Telix Pharmaceuticals | TLX - Selling And Administration Expenses


Telix Pharmaceuticals reported AUD107.02M in Selling and Administration Expenses for its fiscal semester ending in June of 2026.





Selling And Administration Expenses Change Date
Cochlear AUD 449.4M 214.45M Dec/2025
CSL USD 1.23B 498M Dec/2025
Integral Diagnostics AUD 169.98M 18.73M Jun/2024
Mayne Pharma AUD 54.8M 11.94M Jun/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Mesoblast USD 85.89M 57.35M Jun/2026
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Pacific Edge NZD 16.75M 2.42M Jun/2026
Polynovo AUD 17.04M 1.91M Dec/2025
PYC Therapeutics AUD 328.4K 1.8M Dec/2025
Ramsay Health Care AUD 5.29B 3.2M Dec/2024
ResMed USD 285.65M 9.96M Mar/2026
Sonic Healthcare AUD 2.52B 2.46B Dec/2024